Yesenia Kuan, MD

Board Certified Psychiatrist adept at exercising patience and care toward each patient. Comfortable working with individuals suffering from severe psychiatric disorders. Excellent communicator with strengths in engaging patients and listening to needs.

2020-2021 Most outstanding well rounding patient care. Larkin Community Hospital

2019-2020 Most outstanding resident of the year. Larkin Community Hospital2018-2019 Most outstanding well rounding patient care. Larkin Community Hospital

• Florida State License # ME 152339
• ECFMG #0-860-229-4
• GCP
• Board Certified in Psychiatry - November 30, 2022 by American Board of Psychiatry and Neurology #80325

Kuan,Y, and Lopez,J.Delusional Disorder, Somatic Type: An Omitted Diagnosis. Miami Medicine the official Journal of the Dade County Medical Association. Volume 4 (2020 ):21-22.

• 2024 A Phase 3, Randomized, Double blind, Placebo-controlled Study to Evaluate the effects of Oral NMRA-33140 versus Placebo in Participants with Major Depressive Disorder.
• 2023 A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia.
• 2023 A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients with Treatment-Resistant Depression.
• 2023 A randomized, Double-blind, Multicenter, parallel group, Placebo-controlled Study to evaluate the efficacy, safety, and tolerability of Aticaprant 10 mg as an adjunctive Therapy in adult participants with major Depressive Disorder with moderate-to -severe anhedonia and inadequate response to current antidepressant therapy.